etodolac has been researched along with Disease Models, Animal in 22 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine." | 7.78 | Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012) |
| "iii) Treatment with etodolac alone." | 5.35 | Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium. ( Abe, A; Fujii, S; Fujimori, T; Fukui, H; Hiraishi, H; Ichikawa, K; Imura, J; Kono, T; Mukawa, K; Ono, Y; Sekikawa, A; Shinoda, M; Tominaga, K; Tomita, S; Yoshitake, N, 2008) |
| "The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine." | 3.78 | Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012) |
| " Here, we evaluated the influence of aspirin and etodolac, a selective cyclooxygenase-2 inhibitor, on neovascularization using a murine ischemia hind limb model." | 3.76 | The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model. ( Hisatome, I; Kita, Y; Shimizu, T; Tanaka, K; Tsujimoto, S; Uozumi, N; Yamamoto, Y; Yoshida, A, 2010) |
| "Etodolac is a nonsteroidal anti-inflammatory drug which has been demonstrated to protect liver against fibrosis." | 1.40 | Impact of N-acetylcysteine and etodolac treatment on systolic and diastolic function in a rat model of myocardial steatosis induced by high-fat-diet. ( Akkoc, H; Akkus, M; Kelle, I; Topal, AE; Topal, D; Yilmaz, S, 2014) |
| "Several key metastasis-related mediators, such as vascular endothelial growth factor-A, vascular endothelial growth factor-C, and matrix metalloproteinase-9, were inhibited in the presence of etodolac as compared to untreated M2 macrophages." | 1.39 | Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. ( Na, YR; Seok, SH; Son, DI; Yoon, YN, 2013) |
| "When tumors reached 100 mm, mice were treated with CpG-C/vehicle, and 24 hours later the tumor was excised along with P+E/vehicle treatment." | 1.37 | Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. ( Ben-Eliyahu, S; Benish, M; Goldfarb, Y; Levi, B; Melamed, R; Sorski, L, 2011) |
| "iii) Treatment with etodolac alone." | 1.35 | Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium. ( Abe, A; Fujii, S; Fujimori, T; Fukui, H; Hiraishi, H; Ichikawa, K; Imura, J; Kono, T; Mukawa, K; Ono, Y; Sekikawa, A; Shinoda, M; Tominaga, K; Tomita, S; Yoshitake, N, 2008) |
| "Etodolac alleviated heat-evoked hyperalgesia in the CCI rats and the increase in number of TRAP-positive multinucleated osteoclasts on the CCI-side was abrogated, however, it did not inhibit the decrease of BMC and BMD on the CCI-side." | 1.32 | Effect of etodolac, a COX-2 inhibitor, on neuropathic pain in a rat model. ( Gaus, S; Kawamoto, M; Suyama, H; Yuge, O, 2004) |
| "Cyclooxygenases (COXs) are involved in choroidal neovascularization (CNV)." | 1.32 | COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. ( Muranaka, K; Takahashi, H; Tamaki, Y; Uchida, S; Yanagi, Y, 2004) |
| "Etodolac was found to have no effect on 5-lipoxygenase activity." | 1.29 | Effect of anti-inflammatory agent etodolac on antigen-induced contractions of the trachea and lung parenchyma of guinea pigs. ( Hamada, K; Inoue, K; Kimura, K; Shibata, Y; Ueda, F, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 13 (59.09) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 2 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Hirono, J | 1 |
| Sanaki, H | 1 |
| Kitada, K | 1 |
| Sada, H | 1 |
| Suzuki, A | 1 |
| Lie, LK | 1 |
| Segi-Nishida, E | 1 |
| Nakagawa, K | 1 |
| Hasegawa, H | 1 |
| Na, YR | 1 |
| Yoon, YN | 1 |
| Son, DI | 1 |
| Seok, SH | 1 |
| Topal, AE | 1 |
| Akkoc, H | 1 |
| Kelle, I | 1 |
| Yilmaz, S | 1 |
| Topal, D | 1 |
| Akkus, M | 1 |
| Higaki, S | 1 |
| Watanabe, K | 1 |
| Itahashi, M | 1 |
| Shimomura, Y | 1 |
| Tanaka, K | 1 |
| Yamamoto, Y | 1 |
| Tsujimoto, S | 1 |
| Uozumi, N | 1 |
| Kita, Y | 1 |
| Yoshida, A | 1 |
| Shimizu, T | 1 |
| Hisatome, I | 1 |
| Goldfarb, Y | 1 |
| Sorski, L | 1 |
| Benish, M | 1 |
| Levi, B | 1 |
| Melamed, R | 1 |
| Ben-Eliyahu, S | 1 |
| Ito, S | 1 |
| Tajima, K | 1 |
| Nogawa, M | 1 |
| Inoue, N | 1 |
| Kyoi, T | 1 |
| Takahashi, Y | 1 |
| Sasagawa, T | 1 |
| Nakamura, A | 1 |
| Kotera, T | 1 |
| Ueda, M | 1 |
| Yamashita, Y | 1 |
| Banno, K | 1 |
| Chen, WS | 1 |
| Liu, JH | 1 |
| Wei, SJ | 1 |
| Liu, JM | 1 |
| Hong, CY | 1 |
| Yang, WK | 1 |
| Matsunaga, N | 1 |
| Yamada, N | 1 |
| Hirakawa, K | 1 |
| Takeda, J | 1 |
| Kitajima, K | 1 |
| Fujii, S | 2 |
| Horiuchi, H | 1 |
| Hori, H | 1 |
| Chibana, Y | 1 |
| Okuyama, T | 1 |
| Tominaga, K | 2 |
| Ichikawa, K | 2 |
| Ono, Y | 2 |
| Ohkura, Y | 1 |
| Imura, J | 2 |
| Shinoda, M | 2 |
| Chiba, T | 1 |
| Sakamoto, C | 1 |
| Kawamata, H | 1 |
| Fujimori, T | 2 |
| Suyama, H | 1 |
| Kawamoto, M | 1 |
| Gaus, S | 1 |
| Yuge, O | 1 |
| Takahashi, H | 1 |
| Yanagi, Y | 1 |
| Tamaki, Y | 1 |
| Uchida, S | 1 |
| Muranaka, K | 1 |
| Yamamoto, K | 2 |
| Kitayama, W | 2 |
| Denda, A | 2 |
| Morisaki, A | 1 |
| Kuniyasu, H | 2 |
| Inoue, M | 1 |
| Kirita, T | 2 |
| Rahman, A | 1 |
| Yatsuzuka, R | 1 |
| Jiang, S | 1 |
| Ueda, Y | 1 |
| Kamei, C | 1 |
| Sasahira, T | 1 |
| Miyamoto, H | 1 |
| Onuma, H | 1 |
| Shigematsu, H | 1 |
| Suzuki, S | 1 |
| Sakashita, H | 1 |
| Mukawa, K | 1 |
| Yoshitake, N | 1 |
| Abe, A | 1 |
| Kono, T | 1 |
| Sekikawa, A | 1 |
| Fukui, H | 1 |
| Tomita, S | 1 |
| Hiraishi, H | 1 |
| Narita, M | 1 |
| Shimamura, M | 1 |
| Imai, S | 1 |
| Kubota, C | 1 |
| Yajima, Y | 1 |
| Takagi, T | 1 |
| Shiokawa, M | 1 |
| Inoue, T | 1 |
| Suzuki, M | 1 |
| Suzuki, T | 1 |
| Adachi, T | 1 |
| Tajima, Y | 1 |
| Kuroki, T | 1 |
| Mishima, T | 1 |
| Kitasato, A | 1 |
| Tsuneoka, N | 1 |
| Kanematsu, T | 1 |
| Inoue, K | 1 |
| Hamada, K | 1 |
| Ueda, F | 1 |
| Shibata, Y | 1 |
| Kimura, K | 1 |
22 other studies available for etodolac and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Expression of tissue inhibitor of metalloproteinases and matrix metalloproteinases in the ischemic brain of photothrombosis model mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Disease Models, Animal; Endothelia | 2018 |
Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model.
Topics: Animals; Cell Differentiation; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Etodo | 2013 |
Impact of N-acetylcysteine and etodolac treatment on systolic and diastolic function in a rat model of myocardial steatosis induced by high-fat-diet.
Topics: Acetylcysteine; Animals; Cardiomyopathies; Diastole; Diet, High-Fat; Disease Models, Animal; Etodola | 2014 |
Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Benzopyrans; Bromobenzenes; Cornea; | 2009 |
The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model.
Topics: Animals; Aspirin; Bone Marrow Cells; Cell Transplantation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclo | 2010 |
Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses.
Topics: Analysis of Variance; Animals; Chemotherapy, Adjuvant; Disease Models, Animal; Etodolac; Female; Imm | 2011 |
Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Drug Int | 2012 |
Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor.
Topics: Animals; Apoptosis; Cell Survival; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2003 |
[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Cyclooxyg | 2003 |
Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats.
Topics: Animals; Colitis; Colonic Neoplasms; Cyclooxygenase Inhibitors; Disease Models, Animal; Etodolac; In | 2004 |
Effect of etodolac, a COX-2 inhibitor, on neuropathic pain in a rat model.
Topics: Acid Phosphatase; Animals; Bone Density; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2004 |
COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model.
Topics: Angiography; Animals; Choroidal Neovascularization; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
Topics: 4-Nitroquinoline-1-oxide; Administration, Oral; Animals; Anticarcinogenic Agents; Carcinogens; Carci | 2004 |
Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats.
Topics: Animals; Carbazoles; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Electroenc | 2006 |
Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Cell Transformation, Neoplastic; Cycloox | 2006 |
The effect of etodolac on experimental temporomandibular joint osteoarthritis in dogs.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Remodeling; Cartilage, | 2007 |
Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium.
Topics: Animals; Cell Transformation, Neoplastic; Chemoprevention; Colitis; Colonic Neoplasms; Cyclooxygenas | 2008 |
Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relation | 2008 |
Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters.
Topics: Adenocarcinoma, Papillary; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents | 2008 |
Effect of anti-inflammatory agent etodolac on antigen-induced contractions of the trachea and lung parenchyma of guinea pigs.
Topics: Animals; Asthma; Benzoquinones; Disease Models, Animal; Etodolac; Guinea Pigs; Immunization, Passive | 1994 |